2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2006080822v1 18/3/698    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Christensen, E. I. Articles by Nielsen, R. Search for Related Content PubMed PubMed Citation Articles by Christensen, E. I. Articles by Nielsen, R.

Distribution of -Galactosidase A in Normal Human Kidney and Renal Accumulation and Distribution of Recombinant -Galactosidase A in Fabry Mice

Erik I. Christensen^*, Qun Zhou, Søren S. Sørensen, Åse K. Rasmussen, Christian Jacobsen, Ulla Feldt-Rasmussen and Rikke Nielsen^*

^* Department of Cell Biology, Institute of Anatomy, and Department of Medical Biochemistry, University of Aarhus, Aarhus, Denmark; Genzyme Corp., Framingham, Massachusetts; and Department P, Rigshospitalet, Copenhagen, Denmark

Address correspondence to: Dr. Erik Ilsø Christensen, Department of Cell Biology, Institute of Anatomy, Wilh. Meyers Allé, Building 234, University of Aarhus, DK-8000 Aarhus C, Denmark. Phone: +45-8942-3057; Fax: +45-8619-8664; E-mail: eic{at}ana.au.dk

Received for publication August 3, 2006. Accepted for publication January 2, 2007.

Deficiency of lysosomal -galactosidase A (-Gal A) in Fabry disease results in cellular accumulation of globotriaosylceramide (Gl3), often leading to end-stage renal failure. Gl3 accumulates in endothelial, glomerular, and tubular cells. Replacement therapy with recombinant -Gal A to some extent reduces cellular accumulation of Gl3 in the kidney. This study shows high lysosomal expression of -Gal A in all tubular segments and interstitial cells of normal human kidney. However, glomeruli and endothelial cells did not express the enzyme to any significant extent. Recombinant enzyme was taken up by rat yolk sac cells in a receptor-associated protein–inhibitive manner, and surface plasmon resonance experiments revealed binding to megalin, indicating a possible mechanism for uptake of -Gal A in the tubular cells. After infusion into experimental animals or patients, -Gal A was recovered in the urine, indicating glomerular filtration. Recombinant -Gal A was also found in kidneys of normal and -Gal A knockout mice by Western blotting and localized to endosomes and lysosomes in proximal tubules, interstitial cells, and glomerular podocytes by immunocytochemistry and autoradiography but not in vascular endothelial cells. In conclusion, intravenously administered enzyme is taken up by interstitial cells, is to some extent filtered in glomeruli, and is taken up by podocytes and reabsorbed by receptor-mediated endocytosis in proximal tubule cells, directly indicating a potential beneficial effect of enzyme replacement therapy for these cells.

This article has been cited by other articles:

				F. Barbey, O. Lidove, and A. Schwarting Fabry nephropathy: 5 years of enzyme replacement therapy--a short review NDT Plus, February 1, 2008; 1(1): 11 - 19. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673